Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
复制标题
DOI：
10.1002/mds.28206
复制
发表时间：
2020-11
期刊：
影响因子：
--
通讯作者：
Graham D
中科院分区：
文献类型：
--
作者：
Mollenhauer B;Dakna M;Kruse N;Galasko D;Foroud T;Zetterberg H;Schade S;Gera RG;Wang W;Gao F;Frasier M;Chahine LM;Coffey CS;Singleton AB;Simuni T;Weintraub D;Seibyl J;Toga AW;Tanner CM;Kieburtz K;Marek K;Siderowf A;Cedarbaum JM;Hutten SJ;Trenkwalder C;Graham D
本研究的目的是评估神经丝轻链作为帕金森病生物标志物。我们量化了两个独立队列中的神经丝轻链：（1）来自纵向新发帕金森病队列的纵向脑脊液样本和（2）来自帕金森病、其他同源/神经退行性疾病、健康对照、前驱病症和突变携带者的血清样本的大型纵向队列。在帕金森病进展标志物计划队列中，帕金森病患者的平均基线血清神经丝轻链 (13 ± 7.2 pg/mL) 高于对照组 (12 ± 6.7 pg/mL)，P = 0.0336。与对照组相比，帕金森病患者的血清神经丝轻链纵向增加（P < 0.01）。运动评分与神经丝轻链呈正相关，而一些认知评分则呈负相关。与健康对照相比，帕金森病患者血清样本中的神经丝轻链有所增加，并且随着时间和年龄的增长而增加，并且与帕金森病严重程度的临床测量相关。尽管神经丝轻链对帕金森病的特异性较低，但它是第一个基于血液的候选生物标志物，可以支持帕金森病与其他同源/神经退行性疾病的疾病分层，跟踪临床进展，并可能评估对神经保护治疗的反应。然而，使用神经丝轻链作为神经保护干预反应的生物标志物仍有待评估。
The objective of this study was to assess neurofilament light chain as a Parkinson’s disease biomarker. We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson’s disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson’s disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers. In the Parkinson’s Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson’s disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. Serum neurofilament light chain increased longitudinally in Parkinson’s disease patients versus controls (P < 0.01). Motor scores were positively associated with neurofilament light chain, whereas some cognitive scores showed a negative association. Neurofilament light chain in serum samples is increased in Parkinson’s disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson’s disease severity. Although the specificity of neurofilament light chain for Parkinson’s disease is low, it is the first blood-based biomarker candidate that could support disease stratification of Parkinson’s disease versus other cognate/neurodegenerative disorders, track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of neurofilament light chain as a biomarker of response to neuroprotective interventions remains to be assessed.
登录
查看更多内容
影响因子：
12.7
作者：
Halliday, Glenda;Hely, Mariese;Morris, John
通讯作者：
Morris, John
影响因子：
9.9
作者：
Marques, Taina M.;van Rumund, Anouke;Verbeek, Marcel M.
通讯作者：
Verbeek, Marcel M.
影响因子：
29
作者：
Zetterberg H;Skillbäck T;Mattsson N;Trojanowski JQ;Portelius E;Shaw LM;Weiner MW;Blennow K;Alzheimer’s Disease Neuroimaging Initiative
通讯作者：
Alzheimer’s Disease Neuroimaging Initiative
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y
影响因子：
9.9
作者：
Lin, Chin-Hsien;Li, Cheng-Hsuan;Chiu, Ming-Jang
通讯作者：
Chiu, Ming-Jang